Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
- 1 August 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (8) , 2604
- https://doi.org/10.1200/jco.1999.17.8.2604
Abstract
PURPOSE: To determine the principal toxicities, characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of temozolomide (TMZ) on a daily-for-5-days schedule, and recommend a dose for sub...Keywords
This publication has 15 references indexed in Scilit:
- Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.Journal of Clinical Oncology, 1998
- Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitroBritish Journal of Cancer, 1996
- Phase II trial of temozolomide in low-grade non-Hodgkin's lymphomaBritish Journal of Cancer, 1995
- NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNABiochemistry, 1994
- Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cellsBritish Journal of Cancer, 1993
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancerInvestigational New Drugs, 1988
- Phase II evaluation of mitozolomide in ovarian cancerBritish Journal of Cancer, 1988
- Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agentJournal of Medicinal Chemistry, 1984
- Alteration of DNA by 5-(3-methyl-1- triazeno)imidazole-4-carboxamide (NSC-407347)Biochemical Pharmacology, 1976